Show simple item record

dc.creatorTang, Y
dc.creatorSoroush, F
dc.creatorTong, Z
dc.creatorKiani, MF
dc.creatorWang, B
dc.date.accessioned2021-01-25T20:50:11Z
dc.date.available2021-01-25T20:50:11Z
dc.date.issued2017-01-21
dc.identifier.issn1176-9114
dc.identifier.issn1178-2013
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/4951
dc.identifier.other28176940 (pubmed)
dc.identifier.urihttp://hdl.handle.net/20.500.12613/4969
dc.description.abstract© 2017 Tang et al. Chemotherapy has been widely used in breast cancer patients to reduce tumor size. However, most anticancer agents cannot differentiate between cancerous and normal cells, resulting in severe systemic toxicity. In addition, acquired drug resistance during the chemotherapy treatment further decreases treatment efficacy. With the proper treatment strategy, nanodrug carriers, such as liposomes/immunoliposomes, may be able to reduce undesired side effects of chemotherapy, to overcome the acquired multidrug resistance, and to further improve the treatment efficacy. In this study, a novel combinational targeted drug delivery system was developed by encapsulating antiangiogenesis drug bevacizumab into liposomes and encapsulating chemotherapy drug doxorubicin (DOX) into immunoliposomes where the human epidermal growth factor receptor 2 (HER2) antibody was used as a targeting ligand. This novel combinational system was tested in vitro using a HER2 positive and multidrug resistant breast cancer cell line (BT-474/MDR), and in vivo using a xenograft mouse tumor model. In vitro cell culture experiments show that immunoliposome delivery led to a high cell nucleus accumulation of DOX, whereas free DOX was observed mostly near the cell membrane and in cytoplasm due to the action of P-gp. Combining liposomal bevacizumab with immunoliposomal DOX achieved the best tumor growth inhibition and the lowest toxicity. Tumor size decreased steadily within a 60-day observation period indicating a potential synergistic effect between DOX and bevacizumab through the targeted delivery. Our findings clearly indicate that tumor growth was significantly delayed in the combinational liposomal drug delivery group. This novel combinational therapy has great potential for the treatment of patients with HER2/MDR double positive breast cancer.
dc.format.extent671-681
dc.language.isoen
dc.relation.haspartInternational Journal of Nanomedicine
dc.relation.isreferencedbyInforma UK Limited
dc.rightsCC BY-NC
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/
dc.subjectimmunoliposome
dc.subjecttargeted drug delivery
dc.subjectxenograft mouse tumor model
dc.subjectcombination therapy
dc.subjectmultidrug resistance
dc.titleTargeted multidrug delivery system to overcome chemoresistance in breast cancer
dc.typeArticle
dc.type.genreJournal Article
dc.relation.doi10.2147/IJN.S124770
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creator.orcidKiani, Mohammad|0000-0003-1533-0179
dc.date.updated2021-01-25T20:50:07Z
refterms.dateFOA2021-01-25T20:50:11Z


Files in this item

Thumbnail
Name:
Targeted multidrug delivery ...
Size:
812.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

CC BY-NC
Except where otherwise noted, this item's license is described as CC BY-NC